Quick Facts

• Targeted Symptom Management: Utilized in the care of moderate to moderately severe pain.
• Therapeutic Role: May be considered when the administration of a non-opioid pain reliever is not sufficient.

---

What Ultramax Treats: Main Uses and Benefits

Ultramax (a combination of tramadol and acetaminophen) is indicated for use in adults for the temporary management of moderate to moderately severe pain. The product is generally considered for pain states that require a combined approach to relief when treatment with other, single-ingredient pain medications has proven to be inadequate.

Its function is to provide the patient with a mechanism to address pain that is of sufficient intensity to interfere with daily activities. This includes pain following certain medical procedures or in the context of specific conditions as determined by a healthcare provider.

Patients should use this medication only as directed by a licensed practitioner and in accordance with the established duration of therapy to support recovery and promote comfort.

Who Can and Cannot Use Ultramax?

Ultramax (Tramadol/Acetaminophen) eligibility is strictly determined by governmental regulatory labeling. It is officially indicated for use in adults for managing moderate to moderately severe pain, provided the patient does not have any absolute contraindications.

Absolute Contraindications

Ultramax is prohibited for use in the following populations and conditions:

• Children younger than 12 years of age.
• Adolescents under 18 years following tonsillectomy or adenoidectomy.
• Patients with severe hepatic impairment or significant respiratory depression.
• Individuals who are concurrently taking or have recently taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
• Patients with acute intoxication from alcohol, opioids, or psychotropic drugs.

Populations Requiring Restricted Use

Use is not recommended in patients with severe renal impairment or severe respiratory insufficiency. Individuals with moderate renal impairment (CrCl 10 to 30 mL/min) or moderate hepatic impairment may be eligible, but require a prolonged dosage interval as specified in the official label. Use is also not recommended during pregnancy or lactation.

Patients with uncontrolled epilepsy or a history of drug dependence must only be treated under compelling circumstances or are advised against use.

Ultramax Interactions with other medicines and products

Interaction scope

Classification	Interacting Agents	Official Regulatory Constraint/Outcome
Contraindicated	MAO Inhibitors	Prohibited co-administration due to risk of serotonin syndrome and seizures (FDA Label).
Contraindicated	Alcohol	Prohibited due to the increased, combined risk of CNS depression and potential hepatic injury (FDA Label).
Pharmacokinetic	CYP2D6/CYP3A4 Inhibitors	May increase exposure to tramadol and decrease exposure to the active metabolite, potentially reducing analgesic effect or increasing toxicity (EMA SmPC).
Pharmacokinetic	CYP3A4 Inducers	May reduce tramadol exposure, which can result in decreased therapeutic efficacy. Use with Carbamazepine is specifically not recommended (FDA Label, EMA SmPC).
Pharmacodynamic	Serotonergic Drugs (SSRIs, SNRIs)	Increased risk of serotonin syndrome due to additive effects on serotonin levels. Caution is advised (FDA Label).
Pharmacodynamic	Coumarin Derivatives (Warfarin)	Co-administration requires monitoring of Prothrombin Time (PT) and INR due to reports of changes in the anticoagulant effect (NIH, MHRA).
Non-Drug	St. John's Wort	May increase the risk of serotonin syndrome due to its known serotonergic properties (EMA SmPC).

Connection to the overall interaction profile

The official regulatory documents define the Ultramax interaction structure based on two core mechanisms: pharmacokinetic changes via CYP enzymes and pharmacodynamic synergy on the central nervous and serotonergic systems. These interactions result in documented constraints, ranging from absolute prohibition (e.g., MAOIs) to the requirement for mandatory monitoring (e.g., Warfarin) to mitigate the risk of severe, additive adverse events as described in the official prescribing information.

How Ultramax Works

The action of Ultramax is a dual-mechanism strategy that exploits fundamental differences in parasitic physiology, resulting in the destruction or expulsion of targeted parasites. It combines two non-overlapping molecular actions to generate a broad-spectrum physiological effect profile.

---

1. Neuromuscular Blockade via Chloride Channel Agonism

Ivermectin achieves parasite paralysis by directly targeting and acting as an agonist of the unique Glutamate-gated chloride channels ( GluCl) found primarily in nematodes (roundworms). The resulting massive chloride ion influx causes hyperpolarization of the parasite’s nerve and muscle cells, leading to irreversible flaccid paralysis and subsequent expulsion.

---

2. Tegumental Disruption via Calcium Ion Surge

Praziquantel disrupts flatworms ( cestodes and trematodes) by triggering an immediate, uncontrolled surge of calcium ions ( Ca^2+) into the parasite cells. This calcium flood leads to two physiological consequences: severe, sustained spastic paralysis ( tetany) and catastrophic structural disintegration of the parasite’s protective tegument.

---

3. Complementary Dual-Action Synergy

The combination of flaccid paralysis (via Cl^- channel activation) and spastic paralysis with structural damage (via Ca^2+ channel modulation) provides a mechanistic synergy. This complementary approach ensures that two phylogenetically distinct classes of parasites are targeted by chemically and functionally different modes of attack, which establishes a broader physiological effect profile.

Ultramax is administered orally as a fixed-dose combination tablet for the temporary management of pain. The approved administration route is solely oral. The standard adult regimen requires a unit dose of two tablets for initial treatment. This dosing may be repeated every four to six hours as needed to address pain, but the administration frequency must strictly adhere to a maximum of eight tablets within a 24-hour period. Ultramax is indicated for short-term use, generally five days or less. This temporal limitation defines the intended acute nature of the usage protocol.

Regarding consumption context, the tablets may be taken with or without food. A critical usage constraint is the requirement that patients do not exceed a total intake of 4000 mg of Acetaminophen from all sources in 24 hours. Usage patterns for specific populations are detailed: for adults with severe kidney impairment (creatinine clearance < 30 mL/min), the dosing interval must be extended to 12 hours to manage drug clearance. Furthermore, the combination is contraindicated for use in children under the age of 12 years. Discontinuation of the medicine, particularly in physically dependent patients, requires a gradual dosage taper rather than abrupt cessation.

Research evidence / Overview of studies

Overview of Drug A Efficacy Studies

Research has examined Drug A for the management of Symptom X, a common manifestation of Disease D. The majority of published data is derived from two Phase III, randomized, placebo-controlled trials.

• Phase III Trial Results: In a Phase III trial, Drug A was evaluated for its potential to reduce the duration of Symptom X. The trial found a statistically significant association with a reduction in discomfort among participants. The studies primarily focused on adult populations (aged 18–65).

Safety and Tolerability Profile

Clinical trials report a profile of adverse events consistent with mild severity for Drug A, with the most commonly reported events being mild headache and temporary digestive upset.

• Risk Factors Investigated: Drug A has been associated with increased incidence of serious side effects in study participants with a history of condition Y.

• Duration of Study: The studies reviewed focused only on short-term administration.

Combination Therapies

One study explored whether combining Drug A with Drug B was associated with different outcomes compared to monotherapy.

• Findings on Disease Z: Initial data indicates a correlation between Drug A administration and slower progression of disease Z in early-stage patients. These preliminary findings require confirmation through larger, dedicated clinical trials.

Key Studies & References Systematic Review of Combination Therapy: Drug A Plus Drug B Efficacy and Comparative Outcomes

Common questions about Ultramax (FAQ)

Q: Are there any foods or drinks that should be avoided when taking Ultramax?

Official warnings note that the use of alcohol is contraindicated while taking Ultramax due to the high risk of dangerous, combined side effects. Regulatory documents state that the tablets may be taken with or without food, as co-administration with meals is not required.

Q: Is Ultramax known to interact with common over-the-counter cold medicines?

Official warnings describe an increased potential for a serious condition called Serotonin Syndrome when Ultramax is taken with other medicines that affect serotonin levels in the body. Since some over-the-counter cold and cough medicines can have serotonergic effects, official labeling advises caution with other drugs that may cause drowsiness or slow breathing.

Q: Can Ultramax be taken with herbal supplements?

Official documents specifically warn that combining Ultramax with the herbal supplement St. John's Wort may increase the risk of Serotonin Syndrome. This highlights the potential need to review official information regarding interactions with any new medication or supplement.

Q: Can Ultramax affect blood pressure?

Adverse event reports from clinical trials indicate that Ultramax can affect blood pressure, listing both high blood pressure (hypertension) and low blood pressure (hypotension) as less common reported effects. These effects are detailed in the official safety profile for the medicine.

Q: Is Ultramax usually started at a low dose?

Regulatory guidance states that the initial dosing regimen should be tailored to each patient individually. To help reduce the risk of side effects, treatment may be started at a low dose and may be gradually adjusted by the prescribing healthcare provider.

Q: Is Ultramax the same type of medicine as [similar drug name]?

Ultramax is a combination product containing two active components: an opioid analgesic (tramadol) and a non-opioid analgesic (acetaminophen). Official classifications place it within the class of narcotic analgesic combinations.

Q: Does Ultramax cause weight gain?

Regulatory documents list weight decrease as a less common adverse event reported in clinical trials. Weight gain is not listed among the frequently reported side effects in the official safety profile.

Q: Can women who are pregnant or breastfeeding use Ultramax?

Use of Ultramax is not recommended during pregnancy due to documented risks, including the potential for neonatal opioid withdrawal syndrome with prolonged use. Similarly, use is not recommended while breastfeeding because the medicine passes into human milk and is associated with a risk of serious adverse reactions for the infant, such as breathing problems.

Q: Are there any known long-term effects of taking Ultramax?

Ultramax is officially indicated for short-term treatment, generally limited to five days or less. Documented risks associated with use beyond the recommended duration include physical dependence and the potential for withdrawal symptoms upon cessation. Long-term continuous use (over a month) is also listed as a risk factor for certain adrenal problems.

Q: What is the chemical name of Ultramax?

Ultramax is a combination medicine. While the brand name is not a chemical name, the chemical name for the tramadol component is (pm)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. This chemical structure defines the properties of the medicine's opioid component.

Q: Does Ultramax contain any ingredients that cause allergic reactions?

The official label describes the potential for severe allergic reactions (including symptoms like hives and swelling) and serious skin reactions, such as Stevens-Johnson Syndrome, associated with the product’s components.

Q: What is the difference between Ultramax and its generic version?

Ultramax is the brand name for the generic combination of tramadol and acetaminophen. The generic version contains the same active ingredients and is held to the same standards of quality and performance as the brand-name product.

Q: Is it possible to develop a tolerance to Ultramax?

Official warnings state that the body can develop tolerance to Ultramax. Tolerance is a phenomenon where a greater amount of the medicine may be required to achieve the previous level of effect.

Q: Is Ultramax a cure for the condition it treats?

Ultramax is officially indicated for the management of moderate to moderately severe acute pain. It is not described in official documentation as a cure for the underlying pain condition.

Q: What does official guidance say about using Ultramax long-term?

Official guidance emphasizes that Ultramax should be used for the shortest possible duration. The medicine is indicated for short-term use, which is generally limited to five days or less.

Q: Can Ultramax be crushed or split?

Official labeling for this type of opioid product indicates that the tablets are intended to be swallowed whole and should not be crushed, split, or chewed. Modifying the tablet can lead to the rapid, uncontrolled release of the opioid component, which carries a risk of accidental overdose.

Q: Is Ultramax available as an injection or only as a pill?

Ultramax is officially available as an oral tablet containing the fixed-dose combination of tramadol and acetaminophen. The fixed combination is intended for the oral route of administration.

Q: Does taking Ultramax require routine blood tests?

The official label mandates the monitoring of Prothrombin Time (PT) and INR when Ultramax is taken at the same time as blood thinners (coumarin derivatives). Additionally, due to the risk of liver injury (Hepatotoxicity), patients with existing liver issues require special attention.

Q: How long after stopping Ultramax does it stay in your system?

Regulatory pharmacokinetic data describes how the active ingredients are processed by the body. The plasma half-life of tramadol is approximately 6.3 hours, and the half-life of its active metabolite (M1) is approximately 7.4 hours.

Storage and Disposal Requirements for Ultramax (Tramadol/Acetaminophen)

Ultramax must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and freezing.

Due to the risk of fatal accidental overdose upon ingestion, especially by children, Ultramax must be stored in a secure place that is out of the reach and sight of children at all times.

For disposal of unused or expired tablets, patients should primarily use an authorized drug take-back program or DEA-authorized collector. If a take-back program is unavailable, the official regulatory guidance instructs mixing the medication with an undesirable substance (e.g., used coffee grounds) in a sealed container before discarding it in the household trash.